Anti-PCSK9 [FAP2M21]

Name: Anti-PCSK9 [FAP2M21]
SKU: Ab02936
Availability: InStock

Description:

Recombinant monoclonal antibody to PCSK9. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the human B cell clone FAP2M21.

Clone Name:

FAP2M21

Published Application(s):

BLI, functional assay, inhibit, therapeutic, Block, ELISA, FC, IF

Published Species Reactivity:

Human

Products based on this clone:

{{heading}}

Please Select

Ab02936-23.0 Anti-PCSK9 [FAP2M21]
Human
Rabbit IgG
Purified
Ships in 5-6 weeks

Ab02936-10.0 Anti-PCSK9 [FAP2M21]
Human
Human IgG1
Purified
Ships in 5-6 weeks

UniProt Accession Number of Target Protein: Q8NBP7

Alternative Name(s) of Target: NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
Immunogen: The original antibody was generated by panning a fully human scFv phage display library with recombinant human PCSK9. Later on the scFv was transformed into a full length IgG antibody.

Specificity: This antibody specifically binds the module 2 (amino acid residues 530-605) of the C-terminal domain (CTD) of PCSK9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.

Application Notes: This antibody binds human PCSK9 with an extremely slow dissociation rate constant and exert its hypolipidemic effect by blocking PCSK9-LDLR interaction. The binding characterization of this antibody was done using ELISA. Bio-Layer Interferometry (BLI) analysis revealed that the full-length IgG1 antibody FAP2M21 binds to hPCSK9 with a KD as low as 1.42 nM, and a dramatically slow dissociation rate (koff, 4.68 × 10−6 s−1) (PMID: 33647772). This antibody was also used to analyze LDLR expressed on the surface of HepG2 cells using flow cytometry and immunofluorescence staining. This antibody potently inhibited PCSK9-induced reduction of LDL-C uptake in HepG2 cells, with an EC50 of 43.56 nM. When this antibody was injected in C57BL/6 mice expressing human PCSK9, it dose-dependently up-regulated hepatic LDLR levels, and concomitantly reduced serum LDL-C by 3.3% and 37.2%, respectively (PMID: 33647772).

Antibody first published in: Xu et al. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine. 2021 Mar;65:103250. PMID:33647772
Note on publication: Describes the generation of this antibody using phage display technology.